AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01939002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017
Study NCT01939002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen
Study NCT01165112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT01165112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01165112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01165112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01165112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04600505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive 2 inhalations of BGF MDI with propellant 1.
Study NCT04600505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive 2 inhalations of BGF MDI with propellant 2.
Study NCT04600505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive 2 inhalations of BGF MDI with HFA propellant.
Study NCT01926171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib plus WBRT
Description: Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
Study NCT03866785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: interview
Description: The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
Study NCT03866785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Adult Physical Activity Questionnaire (APAQ)
Description: The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
Study NCT03866785 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Activity actigraph
Description: An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
Study NCT03866785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peer training
Description: The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~* Skills in physical activity advice~* Knowledge of functional signs (symptoms)~* Knowledge to examine heart rate and perceived effort rate
Study NCT03866785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity Program
Description: During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months.
Study NCT04073784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with Aptinib and Toripalimab
Description: Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance.
Study NCT02028117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enadenotucirev
Description: Oncolytic Virus
Study NCT02053207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cog-Train Intervention
Description: Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
Study NCT03082534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Cetuximab
Description: Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR.
Study NCT00025259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT00364572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural injection of etanercept
Description: 2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
Study NCT00364572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (control procedure)
Description: Two injections of epidural saline 2 weeks apart
Study NCT04694521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: openSide to end colorectal anastomosis .
Description: open Side to end colorectal anastomosis
Study NCT04694521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open end end to end stapler anastomosis
Description: open end to end stapler anastomosis
Study NCT01702090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir
Description: TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
Study NCT01018472 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis
Description: 1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
Study NCT01018472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
Study NCT01945216 — intervention group
Intervention type: DRUG
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT01118520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perindopril arginine
Description: 10mgs orally daily for the duration of the trial
Study NCT01118520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 5mgs
Description: 5 mgs taken orally daily for the duration of the trial
Study NCT01118520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one daily
Study NCT01185418 — intervention group
Intervention type: DRUG
Intervention: risperidone
Study NCT01185418 — intervention group
Intervention type: DRUG
Intervention: aripiprazole
Study NCT01185418 — intervention group
Intervention type: DRUG
Intervention: haloperidol
Study NCT01185418 — intervention group
Intervention type: DRUG
Intervention: amisulpride
Study NCT01185418 — intervention group
Intervention type: DRUG
Intervention: lactose
Study NCT00869804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic/ Resistance Exercise Intervention
Description: The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
Study NCT00869804 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention control
Study NCT01828619 — intervention group
Intervention type: PROCEDURE
Intervention: modified BuFlu conditioning
Description: The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
Study NCT02439450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viagenpumatucel-L
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
Study NCT02439450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
Study NCT02439450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
Study NCT02439450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
Study NCT03921619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder Sling
Description: soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
Study NCT01391572 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: enlarge irradiation volume
Description: In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
Study NCT01391572 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Small volume radiation
Description: In Arm B, postsurgical radiation target volume includes tumor bed only
Study NCT01391572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT01391572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT01391572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT01391572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT02280902 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
Study NCT00926731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152
Description: Variable dose via a 7-day continuous infusion
Study NCT00926731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDAC (low dose cytosine arabinoside)
Description: 20 mg subcutaneous injection given twice daily
Study NCT00395135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
Study NCT00395135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo BID
Description: Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
Study NCT04072601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
Study NCT04072601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Description: Tablet, can be adjusted to 2 tablets if tolerated
Study NCT03895398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition and psychosocial intervention with community participatory
Description: community participation to ensure the intervention is given to the study subject (underfive children)
Study NCT04234789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cardiopulmonary exercise testing with dynamic hyperinflation maneuver
Description: test performed as recommended by ATS guidelines
Study NCT04234789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: spirometry
Description: test performed as recommended by ATS guidelines
Study NCT04234789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pletysmography
Description: test performed as recommended by ATS guidelines
Study NCT04234789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: forced oscillometry technique
Description: test performed as recommended by ATS guidelines
Study NCT02911740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine LAM Ag test
Description: TB diagnostic assay
Study NCT01865812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Description: All participants were treated with OCA (oral administration, 10 mg, once daily \[QD\]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
Study NCT01184833 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
Study NCT02692040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue
Study NCT02743871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given one dose of placebo for PF-06817024 intravenously
Study NCT02692040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline
Study NCT02692040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study NCT00025259 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Field Radiation Therapy
Description: Undergo IFRT
Study NCT02743871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given one dose of PF-06817024 subcutaneously
Study NCT02743871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given one dose of placebo for PF-06817024 subcutaneously
Study NCT02743871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given two doses of PF-06817024 intravenously
Study NCT02743871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given two doses of PF-06817024 intravenously
Study NCT02743871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given 2 doses intravenously
Study NCT02985892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSASG
Description: Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique.
Study NCT02985892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSPSG
Description: Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles.
Study NCT00025259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally
Study NCT00391469 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Rapid infusion of 2 liters of 4oC normal saline
Description: Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
Study NCT00391469 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Rapid infusion of cold normal saline
Study NCT03073018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril
Description: oral administration, capsules
Study NCT03073018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril
Description: oral administration, capsules
Study NCT03073018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: oral administration, capsules
Study NCT03073018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: oral administration, capsules
Study NCT03073018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fosinopril Placebo
Description: oral administration, capsules
Study NCT03073018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril Placebo
Description: oral administration, capsules
Study NCT03073018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pravastatin Placebo
Description: oral administration, capsules
Study NCT03073018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin Placebo
Description: oral administration, capsules
Study NCT01693874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness-Based Stress Reduction
Study NCT01693874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control (health education)
Description: health education
Study NCT01636505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ghrh antagonist (cetrotide/orgalutran)
Description: cetrotide/orgalutran 0.25 mg
Study NCT01636505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gnrh agonist (suprefact)
Description: suprefact 5.5 ml
Study NCT00532740 — intervention group
Intervention type: RADIATION
Intervention: Yttrium Y 90 glass microspheres
Description: Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
Study NCT01384630 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RA-18C3
Description: 200 mg subcutaneous injection
Study NCT02330302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
Study NCT02330302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
Study NCT02310230 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ExSpiron Respiratory Variation Monitor
Description: Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
Study NCT02310230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExSpiron Respiratory Variation Monitor
Description: Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
Study NCT02055261 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Low frequency DBS of the pedunculopontine nucleus
Study NCT02743871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given 2 doses intravenously
Study NCT02743871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given doses of PF-06817024 intravenously
Study NCT02743871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given doses of Placebo intravenously